Apeiron Capital Investment Revenue Growth Rates (APN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Apeiron Capital Investment Corp   (NYSE: APN)
 

APN's Revenue Growth by Quarter and Year

Apeiron Capital Investment 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

APN Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.00
FY 0.00





APN Revenue first quarter 2022 Y/Y Growth Comment
Apeiron Capital Investment Corp in the first quarter 2022 recorded of $ 0.00 millions.

According to the results reported in the first quarter 2022, Apeiron Capital Investment Corp achieved the best Revenue growth in Biotechnology & Pharmaceuticals industry. While Apeiron Capital Investment Corp ' s Revenue no change of 0% ranks overall at the positon no. in the first quarter 2022.


APN Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   - - - -

Financial Statements
Apeiron Capital Investment 's first quarter 2022 Revenue $ 0.00 millions APN's Income Statement
Apeiron Capital Investment 's first quarter 2021 Revenue $ 0.00 millions Quarterly APN's Income Statement


APN Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   - - - -


Back to APN Growth rate Comparisons >> Back to APN Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Apeiron Capital Investment 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


APN's I. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


APN's I. Quarter Q/Q Revenue Comment


Apeiron Capital Investment 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Mar 31 2023 period, Apeiron Capital Investment 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Apeiron Capital Investment Corp achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Mar 31 2023 period, Apeiron Capital Investment 's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Apeiron Capital Investment Corp achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 






Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
APN's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue no change for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Regenerx Biopharmaceuticals inc -0.01%$ -0.005 millions
Community Health Systems Inc -0.10%$ -0.096 millions
West Pharmaceutical Services Inc -0.47%$ -0.472 millions
Butterfly Network Inc -0.63%$ -0.629 millions
Qhslab Inc -0.71%$ -0.712 millions
Waters Corporation-0.85%$ -0.854 millions
Dariohealth Corp -0.86%$ -0.856 millions
Fresenius Medical Care Ag-1.06%$ -1.058 millions
Acorda Therapeutics Inc -1.22%$ -1.225 millions
Baxter International Inc -1.56%$ -1.565 millions
Kymera Therapeutics Inc -1.62%$ -1.621 millions
Nature s Sunshine Products inc -1.68%$ -1.683 millions
Organon and Co -1.85%$ -1.851 millions
Scientific Industries Inc -2.08%$ -2.077 millions
Amgen Inc -2.13%$ -2.132 millions
Healthcare Services Group Inc -2.24%$ -2.245 millions
Adaptive Biotechnologies Corporation-2.52%$ -2.519 millions
Bristol myers Squibb Company-2.67%$ -2.670 millions
Caredx Inc -2.71%$ -2.712 millions
Biogen Inc -2.72%$ -2.717 millions
Innovage Holding Corp -2.72%$ -2.718 millions
Cardiff Lexington Corporation-2.73%$ -2.727 millions
Apyx Medical Corp-2.81%$ -2.810 millions
Avanos Medical Inc -2.89%$ -2.888 millions
Align Technology inc -3.09%$ -3.090 millions
Bio rad Laboratories Inc -3.32%$ -3.317 millions
Enhabit Inc -3.35%$ -3.354 millions
National Healthcare Corp-3.38%$ -3.377 millions
Thermogenesis Holdings Inc -3.42%$ -3.417 millions
Mesoblast Limited-3.58%$ -3.580 millions


About Apeiron Capital Investment Revenue Growth Rates (APN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Apeiron Capital Investment Corp (CIK 1849011).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001410578-23-001210
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Apeiron Capital Investment Corp ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.